Publications by authors named "A Orleth"
Article Synopsis
- Elevated levels of activated complement proteins in cerebrospinal fluid (CSF) are linked to increased severity of multiple sclerosis (MS) and correlate with brain imaging and disease biomarkers.
- A study involving 239 patients analyzed various complement components and liquid biomarkers in CSF, finding specific proteins like C4a, Ba, and C3a strongly associated with accelerated brain atrophy and lesion formation.
- Results indicate that higher levels of these complement proteins are predictive of greater brain volume loss and increased development of lesions, suggesting their potential role as biomarkers for disease progression in MS.
Background: Treatment decisions for persons with relapsing-remitting multiple sclerosis (RRMS) rely on clinical and radiological disease activity, the benefit-harm profile of drug therapy, and preferences of patients and physicians. However, there is limited evidence to support evidence-based personalized decision-making on how to adapt disease-modifying therapy treatments targeting no evidence of disease activity, while achieving better patient-relevant outcomes, fewer adverse events, and improved care. Serum neurofilament light chain (sNfL) is a sensitive measure of disease activity that captures and prognosticates disease worsening in RRMS.
View Article and Find Full Text PDFComplement Activation Is Associated With Disease Severity in Multiple Sclerosis.
Neurol Neuroimmunol Neuroinflamm
March 2024
Article Synopsis
- The study investigates the role of complement components (CCs) and activation products (CAPs) in multiple sclerosis (MS), particularly focusing on how their levels are affected by the presence of intrathecal IgM synthesis, which is linked to higher disease severity.
- By analyzing samples from 112 clinically isolated syndrome (CIS) patients and 127 MS patients, it was found that specific complement levels in the cerebrospinal fluid (CSF) were significantly higher in those with MS compared to control groups.
- Key findings indicate that increased levels of complement components like C3a and C4a in the CSF correlate with worse disability and disease progression in MS patients, emphasizing the relationship between complement activation and neurodegeneration in
Background: Granulocyte invasion into the brain is a pathoanatomical feature differentiating neuromyelitis optica spectrum disorder (NMOSD) from multiple sclerosis (MS). We aimed to determine whether granulocyte activation markers (GAM) in cerebrospinal fluid (CSF) can be used as a biomarker to distinguish NMOSD from MS, and whether levels associate with neurological impairment.
Methods: We quantified CSF levels of five GAM (neutrophil elastase, myeloperoxidase, neutrophil gelatinase-associated lipocalin, matrixmetalloproteinase-8, tissue inhibitor of metalloproteinase-1), as well as a set of inflammatory and tissue-destruction markers, known to be upregulated in NMOSD and MS (neurofilament light chain, glial fibrillary acidic protein, S100B, matrix metalloproteinase-9, intercellular adhesion molecule-1, vascular cellular adhesion molecule-1), in two cohorts of patients with mixed NMOSD and relapsing-remitting multiple sclerosis (RRMS).
Importance: There is a lack of validated biomarkers for disability progression independent of relapse activity (PIRA) in multiple sclerosis (MS).
Objective: To determine how serum glial fibrillary acidic protein (sGFAP) and serum neurofilament light chain (sNfL) correlate with features of disease progression vs acute focal inflammation in MS and how they can prognosticate disease progression.
Design, Setting, And Participants: Data were acquired in the longitudinal Swiss MS cohort (SMSC; a consortium of tertiary referral hospitals) from January 1, 2012, to October 20, 2022.